• Home
  • Product Information
  • Reconstitution
  • How Nuwiq is made
    • Packaging & Storage
  • Resources
nuwiq.ca nuwiq.ca nuwiq.ca nuwiq.ca
  • Home
  • Product Information
  • Reconstitution
  • How Nuwiq is made
    • Packaging & Storage
  • Resources

ABOUT NUWIQ®

Nuwiq® is indicated for the treatment and prophylaxis of bleeding in persons with hemophilia of all ages suffering with hemophilia A (congenital factor VIII deficiency). Nuwiq® can also be used in hemophilia A patients undergoing major or minor surgical procedures.

Nuwiq®

Nuwiq is used for the treatment and prophylaxis of bleeding in adults and children of all ages with hemophilia A (congenital factor VIII deficiency). Hemophilia is a bleeding disorder in which a person’s blood does not clot properly. Hemophilia A is the result of a deficiency of factor VIII (FVIII) protein, this protein is necessary to allow the proper formation of a clot to stop bleeding.

Hemophilia A can be treated by giving factor VIII concentrate to replace the deficient factor and raise the levels of FVIII. This helps the blood to clot. Nuwiq is a coagulation factor concentrate made by recombinant technology, and its medicinal ingredient is antihemophilic Factor (Recombinant, B-Domain deleted).

SUMMARY OF PRODUCT CHARACTERISTICS (Part III: Consumer Information)

Image

Copyright © 2020 Octapharma I Legal Statement I Privacy Statement I Sitemap
Octapharma Canada Inc. | 308 - 214 King Street West | Toronto, ON | M5H 3S6

  • enEnglish
  • frFrançais